Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism

Ninety-three hyperthyroid patients were treated with 1 dose of iodine-131 (131I) during the past 10 years. Thirty-three were pretreated with propylthiouracil (PTU), 22 with methimazole (MMI), and 38 received no antithyroid drugs (ATD). ATD were discontinued 5-55 days before 131I therapy in three fou...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The journal of clinical endocrinology and metabolism 1998-02, Vol.83 (2), p.685-687
Hauptverfasser: IMSEIS, R. E, VANMIDDLESWORTH, L, MASSIE, J. D, BUSH, A. J, VANMIDDLESWORTH, N. R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 687
container_issue 2
container_start_page 685
container_title The journal of clinical endocrinology and metabolism
container_volume 83
creator IMSEIS, R. E
VANMIDDLESWORTH, L
MASSIE, J. D
BUSH, A. J
VANMIDDLESWORTH, N. R
description Ninety-three hyperthyroid patients were treated with 1 dose of iodine-131 (131I) during the past 10 years. Thirty-three were pretreated with propylthiouracil (PTU), 22 with methimazole (MMI), and 38 received no antithyroid drugs (ATD). ATD were discontinued 5-55 days before 131I therapy in three fourths of the cases and more than 4 months before therapy in one fourth of the cases. The frequency of cures in the 3 groups, 6-8 months after radioiodine therapy, was retrospectively studied. The cure rate among those who discontinued PTU for 5-55 days before 131I was significantly reduced (24%), compared with those who discontinued MMI for the same duration (61%) or those who received no ATD (66%). When PTU was discontinued for more than 4 months, the cure rate was similar to those who received no ATD. It is concluded that if ATD are used as initial therapy for hyperthyroidism, then PTU (but not MMI) may reduce the therapeutic efficacy of subsequent 131I. The reduction in cure rate was observed even when PTU was discontinued for as long as 55 days before 131I therapy. To our knowledge, this is the first report to compare, in one study, the effects of pretreatment with PTU and MMI on 131I therapy.
doi_str_mv 10.1210/jc.83.2.685
format Article
fullrecord <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_9467593</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>9467593</sourcerecordid><originalsourceid>FETCH-LOGICAL-c246t-98d758825786dceedef0bce5cc71e0263074e1f9a3111ee2b2ecdbc15d90ce183</originalsourceid><addsrcrecordid>eNo9UEtLxDAYDKKs6-rJs5CD19Z8adMkR1l8wYIeFLwtafKVZumLNEXrr3cXFw_DwMwwMEPINbAUOLC7nU1VlvK0UOKELEHnIpGg5SlZMsYh0ZJ_npOLcdwxBnkusgVZ6LyQQmdL8v0WMAY0scUu0i8fazqEfpibWPt-Csb6hpZTpF0faYt7sTU_fYM0oJssjjTWeEAwA07RW4pV5a2xM-0r6nvnO0wgA-o7Ws8DhljPoffOj-0lOatMM-LVkVfk4_Hhff2cbF6fXtb3m8TyvIiJVk4KpbiQqnAW0WHFSovCWgnIeJExmSNU2mQAgMhLjtaVFoTTzCKobEVu_nqHqWzRbYewnxDm7fGBvX979M1oTVMF01k__sc4CHWI_QJyu21B</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>IMSEIS, R. E ; VANMIDDLESWORTH, L ; MASSIE, J. D ; BUSH, A. J ; VANMIDDLESWORTH, N. R</creator><creatorcontrib>IMSEIS, R. E ; VANMIDDLESWORTH, L ; MASSIE, J. D ; BUSH, A. J ; VANMIDDLESWORTH, N. R</creatorcontrib><description>Ninety-three hyperthyroid patients were treated with 1 dose of iodine-131 (131I) during the past 10 years. Thirty-three were pretreated with propylthiouracil (PTU), 22 with methimazole (MMI), and 38 received no antithyroid drugs (ATD). ATD were discontinued 5-55 days before 131I therapy in three fourths of the cases and more than 4 months before therapy in one fourth of the cases. The frequency of cures in the 3 groups, 6-8 months after radioiodine therapy, was retrospectively studied. The cure rate among those who discontinued PTU for 5-55 days before 131I was significantly reduced (24%), compared with those who discontinued MMI for the same duration (61%) or those who received no ATD (66%). When PTU was discontinued for more than 4 months, the cure rate was similar to those who received no ATD. It is concluded that if ATD are used as initial therapy for hyperthyroidism, then PTU (but not MMI) may reduce the therapeutic efficacy of subsequent 131I. The reduction in cure rate was observed even when PTU was discontinued for as long as 55 days before 131I therapy. To our knowledge, this is the first report to compare, in one study, the effects of pretreatment with PTU and MMI on 131I therapy.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/jc.83.2.685</identifier><identifier>PMID: 9467593</identifier><identifier>CODEN: JCEMAZ</identifier><language>eng</language><publisher>Bethesda, MD: Endocrine Society</publisher><subject>Adult ; Antithyroid Agents ; Biological and medical sciences ; Female ; Hormones. Endocrine system ; Humans ; Hyperthyroidism - drug therapy ; Hyperthyroidism - radiotherapy ; Iodine Radioisotopes - therapeutic use ; Male ; Medical sciences ; Methimazole - adverse effects ; Methimazole - therapeutic use ; Middle Aged ; Pharmacology. Drug treatments ; Premedication ; Propylthiouracil - adverse effects ; Propylthiouracil - therapeutic use ; Retrospective Studies ; Treatment Outcome</subject><ispartof>The journal of clinical endocrinology and metabolism, 1998-02, Vol.83 (2), p.685-687</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c246t-98d758825786dceedef0bce5cc71e0263074e1f9a3111ee2b2ecdbc15d90ce183</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2158593$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9467593$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>IMSEIS, R. E</creatorcontrib><creatorcontrib>VANMIDDLESWORTH, L</creatorcontrib><creatorcontrib>MASSIE, J. D</creatorcontrib><creatorcontrib>BUSH, A. J</creatorcontrib><creatorcontrib>VANMIDDLESWORTH, N. R</creatorcontrib><title>Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>Ninety-three hyperthyroid patients were treated with 1 dose of iodine-131 (131I) during the past 10 years. Thirty-three were pretreated with propylthiouracil (PTU), 22 with methimazole (MMI), and 38 received no antithyroid drugs (ATD). ATD were discontinued 5-55 days before 131I therapy in three fourths of the cases and more than 4 months before therapy in one fourth of the cases. The frequency of cures in the 3 groups, 6-8 months after radioiodine therapy, was retrospectively studied. The cure rate among those who discontinued PTU for 5-55 days before 131I was significantly reduced (24%), compared with those who discontinued MMI for the same duration (61%) or those who received no ATD (66%). When PTU was discontinued for more than 4 months, the cure rate was similar to those who received no ATD. It is concluded that if ATD are used as initial therapy for hyperthyroidism, then PTU (but not MMI) may reduce the therapeutic efficacy of subsequent 131I. The reduction in cure rate was observed even when PTU was discontinued for as long as 55 days before 131I therapy. To our knowledge, this is the first report to compare, in one study, the effects of pretreatment with PTU and MMI on 131I therapy.</description><subject>Adult</subject><subject>Antithyroid Agents</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Hormones. Endocrine system</subject><subject>Humans</subject><subject>Hyperthyroidism - drug therapy</subject><subject>Hyperthyroidism - radiotherapy</subject><subject>Iodine Radioisotopes - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methimazole - adverse effects</subject><subject>Methimazole - therapeutic use</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Premedication</subject><subject>Propylthiouracil - adverse effects</subject><subject>Propylthiouracil - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9UEtLxDAYDKKs6-rJs5CD19Z8adMkR1l8wYIeFLwtafKVZumLNEXrr3cXFw_DwMwwMEPINbAUOLC7nU1VlvK0UOKELEHnIpGg5SlZMsYh0ZJ_npOLcdwxBnkusgVZ6LyQQmdL8v0WMAY0scUu0i8fazqEfpibWPt-Csb6hpZTpF0faYt7sTU_fYM0oJssjjTWeEAwA07RW4pV5a2xM-0r6nvnO0wgA-o7Ws8DhljPoffOj-0lOatMM-LVkVfk4_Hhff2cbF6fXtb3m8TyvIiJVk4KpbiQqnAW0WHFSovCWgnIeJExmSNU2mQAgMhLjtaVFoTTzCKobEVu_nqHqWzRbYewnxDm7fGBvX979M1oTVMF01k__sc4CHWI_QJyu21B</recordid><startdate>19980201</startdate><enddate>19980201</enddate><creator>IMSEIS, R. E</creator><creator>VANMIDDLESWORTH, L</creator><creator>MASSIE, J. D</creator><creator>BUSH, A. J</creator><creator>VANMIDDLESWORTH, N. R</creator><general>Endocrine Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>19980201</creationdate><title>Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism</title><author>IMSEIS, R. E ; VANMIDDLESWORTH, L ; MASSIE, J. D ; BUSH, A. J ; VANMIDDLESWORTH, N. R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c246t-98d758825786dceedef0bce5cc71e0263074e1f9a3111ee2b2ecdbc15d90ce183</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Antithyroid Agents</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Hormones. Endocrine system</topic><topic>Humans</topic><topic>Hyperthyroidism - drug therapy</topic><topic>Hyperthyroidism - radiotherapy</topic><topic>Iodine Radioisotopes - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methimazole - adverse effects</topic><topic>Methimazole - therapeutic use</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Premedication</topic><topic>Propylthiouracil - adverse effects</topic><topic>Propylthiouracil - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>IMSEIS, R. E</creatorcontrib><creatorcontrib>VANMIDDLESWORTH, L</creatorcontrib><creatorcontrib>MASSIE, J. D</creatorcontrib><creatorcontrib>BUSH, A. J</creatorcontrib><creatorcontrib>VANMIDDLESWORTH, N. R</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>IMSEIS, R. E</au><au>VANMIDDLESWORTH, L</au><au>MASSIE, J. D</au><au>BUSH, A. J</au><au>VANMIDDLESWORTH, N. R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>1998-02-01</date><risdate>1998</risdate><volume>83</volume><issue>2</issue><spage>685</spage><epage>687</epage><pages>685-687</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><coden>JCEMAZ</coden><abstract>Ninety-three hyperthyroid patients were treated with 1 dose of iodine-131 (131I) during the past 10 years. Thirty-three were pretreated with propylthiouracil (PTU), 22 with methimazole (MMI), and 38 received no antithyroid drugs (ATD). ATD were discontinued 5-55 days before 131I therapy in three fourths of the cases and more than 4 months before therapy in one fourth of the cases. The frequency of cures in the 3 groups, 6-8 months after radioiodine therapy, was retrospectively studied. The cure rate among those who discontinued PTU for 5-55 days before 131I was significantly reduced (24%), compared with those who discontinued MMI for the same duration (61%) or those who received no ATD (66%). When PTU was discontinued for more than 4 months, the cure rate was similar to those who received no ATD. It is concluded that if ATD are used as initial therapy for hyperthyroidism, then PTU (but not MMI) may reduce the therapeutic efficacy of subsequent 131I. The reduction in cure rate was observed even when PTU was discontinued for as long as 55 days before 131I therapy. To our knowledge, this is the first report to compare, in one study, the effects of pretreatment with PTU and MMI on 131I therapy.</abstract><cop>Bethesda, MD</cop><pub>Endocrine Society</pub><pmid>9467593</pmid><doi>10.1210/jc.83.2.685</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0021-972X
ispartof The journal of clinical endocrinology and metabolism, 1998-02, Vol.83 (2), p.685-687
issn 0021-972X
1945-7197
language eng
recordid cdi_pubmed_primary_9467593
source Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adult
Antithyroid Agents
Biological and medical sciences
Female
Hormones. Endocrine system
Humans
Hyperthyroidism - drug therapy
Hyperthyroidism - radiotherapy
Iodine Radioisotopes - therapeutic use
Male
Medical sciences
Methimazole - adverse effects
Methimazole - therapeutic use
Middle Aged
Pharmacology. Drug treatments
Premedication
Propylthiouracil - adverse effects
Propylthiouracil - therapeutic use
Retrospective Studies
Treatment Outcome
title Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T23%3A28%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pretreatment%20with%20propylthiouracil%20but%20not%20methimazole%20reduces%20the%20therapeutic%20efficacy%20of%20iodine-131%20in%20hyperthyroidism&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=IMSEIS,%20R.%20E&rft.date=1998-02-01&rft.volume=83&rft.issue=2&rft.spage=685&rft.epage=687&rft.pages=685-687&rft.issn=0021-972X&rft.eissn=1945-7197&rft.coden=JCEMAZ&rft_id=info:doi/10.1210/jc.83.2.685&rft_dat=%3Cpubmed_pasca%3E9467593%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/9467593&rfr_iscdi=true